Figure 6.

The improvement of HDAC inhibitor treatment on product purity of BE3 required the presence of UGI

(A) Representative Sanger sequencing results and EditR analysis showing the effect of HDAC inhibitors on the editing of site 28 by BE-NO-UGI. (B) The effects of HDAC inhibitor treatment on the C-to-T (left panel) and C-to-G/A (right panel) conversions of BE-NO-UGI. (C) Quantification of the product distribution of (B). Each experiment was repeated at least three times. Data are represented as mean ± SD; asterisks indicate statistically significant differences between DMSO-treated cells and HDAC inhibitor-treated cells (∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001). Base editing efficiencies were analyzed using Sanger sequencing and EditR calculation.